-
2
-
-
34147124852
-
Islet dysfunction: an underlying defect in the pathophysiology of type 2 diabetes
-
Pratley R. Islet dysfunction: an underlying defect in the pathophysiology of type 2 diabetes. Endocrinol Metab Clin North Am. 2006;35(suppl 1):6-11.
-
(2006)
Endocrinol Metab Clin North Am.
, vol.35
, Issue.SUPPL. 1
, pp. 6-11
-
-
Pratley, R.1
-
3
-
-
58149468464
-
Can newer therapies delay the progression of type 2 diabetes mellitus?
-
Horton ES. Can newer therapies delay the progression of type 2 diabetes mellitus? Endocr Pract. 2008;14:625-638.
-
(2008)
Endocr Pract.
, vol.14
, pp. 625-638
-
-
Horton, E.S.1
-
4
-
-
75149180515
-
Standards of medical care in diabetes-2010
-
American Diabetes Association.
-
American Diabetes Association. Standards of medical care in diabetes-2010. Diabetes Care. 2010;33(suppl 1):S11-S61.
-
(2010)
Diabetes Care.
, vol.33
, Issue.SUPPL. 1
-
-
-
5
-
-
77649091668
-
American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus
-
Rodbard HW, Blonde L, Braithwaite SS, et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract. 2007;13(suppl 1):1-68.
-
(2007)
Endocr Pract.
, vol.13
, Issue.SUPPL. 1
, pp. 1-68
-
-
Rodbard, H.W.1
Blonde, L.2
Braithwaite, S.S.3
-
6
-
-
38949210220
-
Effect of a multifactorial intervention on mortality in type 2 diabetes
-
Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008;358:580-591.
-
(2008)
N Engl J Med.
, vol.358
, pp. 580-591
-
-
Gaede, P.1
Lund-Andersen, H.2
Parving, H.H.3
Pedersen, O.4
-
7
-
-
0037472879
-
Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes
-
Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003;348:383-393.
-
(2003)
N Engl J Med.
, vol.348
, pp. 383-393
-
-
Gaede, P.1
Vedel, P.2
Larsen, N.3
-
9
-
-
0347133334
-
Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes
-
Saydah SH, Fradkin J, Cowie CC. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA. 2004;291:335-342.
-
(2004)
JAMA.
, vol.291
, pp. 335-342
-
-
Saydah, S.H.1
Fradkin, J.2
Cowie, C.C.3
-
11
-
-
3042714557
-
The burden of treatment failure in type 2 diabetes
-
Brown JB, Nichols GA, Perry A. The burden of treatment failure in type 2 diabetes. Diabetes Care. 2004;27:1535-1540.
-
(2004)
Diabetes Care.
, vol.27
, pp. 1535-1540
-
-
Brown, J.B.1
Nichols, G.A.2
Perry, A.3
-
12
-
-
34250212715
-
Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes
-
Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356:2457-2471.
-
(2007)
N Engl J Med.
, vol.356
, pp. 2457-2471
-
-
Nissen, S.E.1
Wolski, K.2
-
13
-
-
70350051492
-
Trends in medication use among US adults with diabetes mellitus: glycemic control at the expense of controlling cardiovascular risk factors
-
Mann DM, Woodward M, Ye F, et al. Trends in medication use among US adults with diabetes mellitus: glycemic control at the expense of controlling cardiovascular risk factors. Arch Intern Med. 2009;169:1718-1720.
-
(2009)
Arch Intern Med.
, vol.169
, pp. 1718-1720
-
-
Mann, D.M.1
Woodward, M.2
Ye, F.3
-
14
-
-
75549091263
-
Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control
-
Rodbard HW, Jellinger PS, Davidson JA, et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract. 2009;15:540-559.
-
(2009)
Endocr Pract.
, vol.15
, pp. 540-559
-
-
Rodbard, H.W.1
Jellinger, P.S.2
Davidson, J.A.3
-
15
-
-
37749000859
-
Suboptimal control of glycemia, blood pressure, and LDL cholesterol in overweight adults with diabetes: the Look AHEAD Study
-
Bertoni AG, Clark JM, Feeney P, et al. Suboptimal control of glycemia, blood pressure, and LDL cholesterol in overweight adults with diabetes: the Look AHEAD Study. J Diabetes Complications. 2008;22:1-9.
-
(2008)
J Diabetes Complications.
, vol.22
, pp. 1-9
-
-
Bertoni, A.G.1
Clark, J.M.2
Feeney, P.3
-
16
-
-
12844281026
-
Quality of diabetes care in U.S. academic medical centers: low rates of medical regimen change
-
University HealthSystem Consortium Diabetes Benchmarking Project Team.
-
Grant RW, Buse JB, Meigs JB; University HealthSystem Consortium Diabetes Benchmarking Project Team. Quality of diabetes care in U.S. academic medical centers: low rates of medical regimen change. Diabetes Care. 2005;28:337-442.
-
(2005)
Diabetes Care.
, vol.28
, pp. 337-442
-
-
Grant, R.W.1
Buse, J.B.2
Meigs, J.B.3
-
17
-
-
33749006625
-
Effect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitus
-
Ho PM, Rumsfeld JS, Masoudi FA, et al. Effect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitus. Arch Intern Med. 2006;166:1836-1841.
-
(2006)
Arch Intern Med.
, vol.166
, pp. 1836-1841
-
-
Ho, P.M.1
Rumsfeld, J.S.2
Masoudi, F.A.3
-
18
-
-
17844391245
-
Adherence to pharmacologic therapy in patients with type 2 diabetes mellitus
-
Rubin RR. Adherence to pharmacologic therapy in patients with type 2 diabetes mellitus. Am J Med. 2005;118(suppl 5A):27S-34S.
-
(2005)
Am J Med.
, vol.118
, Issue.SUPPL. 5A
-
-
Rubin, R.R.1
-
19
-
-
34249300509
-
Educating patients with type 2 diabetes on a new class of drug, dipeptidyl peptidase 4 inhibitors
-
Siminerio L. Educating patients with type 2 diabetes on a new class of drug, dipeptidyl peptidase 4 inhibitors. Diabetes Educ. 2007;33(suppl 5):111S-113S.
-
(2007)
Diabetes Educ.
, vol.33
, Issue.SUPPL. 5
-
-
Siminerio, L.1
-
20
-
-
0842311565
-
Problems paying out-of-pocket medication costs among older adults with diabetes
-
Piette JD, Heisler M, Wagner TH. Problems paying out-of-pocket medication costs among older adults with diabetes. Diabetes Care. 2004;27:384-391.
-
(2004)
Diabetes Care.
, vol.27
, pp. 384-391
-
-
Piette, J.D.1
Heisler, M.2
Wagner, T.H.3
-
21
-
-
70449677664
-
Cost-related nonadherence to medications among patients with diabetes and chronic pain: factors beyond finances
-
Kurlander JE, Kerr EA, Krein S, et al. Cost-related nonadherence to medications among patients with diabetes and chronic pain: factors beyond finances. Diabetes Care. 2009;32:2143-2148.
-
(2009)
Diabetes Care.
, vol.32
, pp. 2143-2148
-
-
Kurlander, J.E.1
Kerr, E.A.2
Krein, S.3
-
22
-
-
53849118827
-
Effect of prescription copayments on adherence and treatment failure with oral antidiabetic medications
-
Barron J, Wahl P, Fisher M, Plauschinat C. Effect of prescription copayments on adherence and treatment failure with oral antidiabetic medications. P T. 2008;33:532-553.
-
(2008)
P T.
, vol.33
, pp. 532-553
-
-
Barron, J.1
Wahl, P.2
Fisher, M.3
Plauschinat, C.4
-
23
-
-
69449103894
-
Effect of patient medication cost share on adherence and glycemic control
-
Hunt J, Rozenfeld Y, Shenolikar R. Effect of patient medication cost share on adherence and glycemic control. Manag Care. 2009;18:47-53.
-
(2009)
Manag Care.
, vol.18
, pp. 47-53
-
-
Hunt, J.1
Rozenfeld, Y.2
Shenolikar, R.3
-
24
-
-
0032837107
-
Diabetes in urban African-Americans. XV. Identification of barriers to provider adherence to management protocols
-
El-Kebbi IM, Ziemer DC, Gallina DL, et al. Diabetes in urban African-Americans. XV. Identification of barriers to provider adherence to management protocols. Diabetes Care. 1999;22:1617-1620.
-
(1999)
Diabetes Care.
, vol.22
, pp. 1617-1620
-
-
El-Kebbi, I.M.1
Ziemer, D.C.2
Gallina, D.L.3
-
25
-
-
0042309664
-
Hypertension management in patients with diabetes: the need for more aggressive therapy
-
Berlowitz DR, Ash AS, Hickey EC, et al. Hypertension management in patients with diabetes: the need for more aggressive therapy. Diabetes Care. 2003;26:355-359.
-
(2003)
Diabetes Care.
, vol.26
, pp. 355-359
-
-
Berlowitz, D.R.1
Ash, A.S.2
Hickey, E.C.3
-
26
-
-
0031852544
-
Nurse-mediated cholesterol management compared with enhanced primary care in siblings of individuals with premature coronary disease
-
Becker DM, Raqueno JV, Yook RM, et al. Nurse-mediated cholesterol management compared with enhanced primary care in siblings of individuals with premature coronary disease. Arch Intern Med. 1998;158:1533-1539.
-
(1998)
Arch Intern Med.
, vol.158
, pp. 1533-1539
-
-
Becker, D.M.1
Raqueno, J.V.2
Yook, R.M.3
-
27
-
-
78650430047
-
Clinical inertia in patients with T2DM requiring insulin in family practice
-
Harris SB, Kapor J, Lank CN, et al. Clinical inertia in patients with T2DM requiring insulin in family practice. Can Fam Physician. 2010;56:e418-e424.
-
(2010)
Can Fam Physician.
, vol.56
-
-
Harris, S.B.1
Kapor, J.2
Lank, C.N.3
-
28
-
-
1242314755
-
Clinical inertia in the management of type 2 diabetes metabolic risk factors
-
Grant RW, Cagliero E, Dubey AK, et al. Clinical inertia in the management of type 2 diabetes metabolic risk factors. Diabet Med. 2004;21:150-155.
-
(2004)
Diabet Med.
, vol.21
, pp. 150-155
-
-
Grant, R.W.1
Cagliero, E.2
Dubey, A.K.3
-
29
-
-
23944459590
-
Clinical inertia contributes to poor diabetes control in a primary care setting
-
Ziemer DC, Miller CD, Rhee MK, et al. Clinical inertia contributes to poor diabetes control in a primary care setting. Diabetes Educ. 2005;31:564-571.
-
(2005)
Diabetes Educ.
, vol.31
, pp. 564-571
-
-
Ziemer, D.C.1
Miller, C.D.2
Rhee, M.K.3
-
30
-
-
14744274123
-
Clinical inertia in response to inadequate glycemic control: do specialists differ from primary care physicians?
-
Shah BR, Hux JE, Laupacis A, et al. Clinical inertia in response to inadequate glycemic control: do specialists differ from primary care physicians? Diabetes Care. 2005;28:600-606.
-
(2005)
Diabetes Care.
, vol.28
, pp. 600-606
-
-
Shah, B.R.1
Hux, J.E.2
Laupacis, A.3
-
31
-
-
34147109354
-
Relationship between patient medication adherence and subsequent clinical inertia in type 2 diabetes glycemic management
-
Grant R, Adams AS, Trinacty CM, et al. Relationship between patient medication adherence and subsequent clinical inertia in type 2 diabetes glycemic management. Diabetes Care. 2007;30: 807-812.
-
(2007)
Diabetes Care.
, vol.30
, pp. 807-812
-
-
Grant, R.1
Adams, A.S.2
Trinacty, C.M.3
-
32
-
-
0029111811
-
Managing hypertension in general practice: can we do better?
-
Hosie J, Wiklund I. Managing hypertension in general practice: can we do better? J Hum Hypertens. 1995;9(suppl 2):S15-S18.
-
(1995)
J Hum Hypertens.
, vol.9
, Issue.SUPPL. 2
-
-
Hosie, J.1
Wiklund, I.2
-
33
-
-
60849117256
-
Impact of direct-to-consumer advertising (DTCA) on patient health-related behaviors and issues
-
Polen HH, Khanfar NM, Clauson KA. Impact of direct-to-consumer advertising (DTCA) on patient health-related behaviors and issues. Health Mark Q. 2009;26:42-55.
-
(2009)
Health Mark Q.
, vol.26
, pp. 42-55
-
-
Polen, H.H.1
Khanfar, N.M.2
Clauson, K.A.3
-
34
-
-
67649199624
-
Clinical practice effect of rosiglitazone discontinuation on glycemic control
-
Fanning EL, Weissman PN, Menditto LA. Clinical practice effect of rosiglitazone discontinuation on glycemic control. Endocr Pract. 2009;15:270-272.
-
(2009)
Endocr Pract.
, vol.15
, pp. 270-272
-
-
Fanning, E.L.1
Weissman, P.N.2
Menditto, L.A.3
-
35
-
-
68949214466
-
Lay media reporting of rosiglitazone risk: extent, messaging and quality of reporting
-
Rabi DM, Lewin AM, Brown GE, et al. Lay media reporting of rosiglitazone risk: extent, messaging and quality of reporting. Cardiovasc Diabetol. 2009;8:40.
-
(2009)
Cardiovasc Diabetol.
, vol.8
, pp. 40
-
-
Rabi, D.M.1
Lewin, A.M.2
Brown, G.E.3
-
36
-
-
45149131667
-
Effects of intensive glucose lowering in type 2 diabetes
-
Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545-2559.
-
(2008)
N Engl J Med.
, vol.358
, pp. 2545-2559
-
-
Gerstein, H.C.1
Miller, M.E.2
Byington, R.P.3
-
37
-
-
58149389215
-
Glucose control and vascular complications in veterans with type 2 diabetes
-
Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360:129-139.
-
(2009)
N Engl J Med.
, vol.360
, pp. 129-139
-
-
Duckworth, W.1
Abraira, C.2
Moritz, T.3
-
38
-
-
45149133036
-
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
-
Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560-2572.
-
(2008)
N Engl J Med.
, vol.358
, pp. 2560-2572
-
-
Patel, A.1
MacMahon, S.2
Chalmers, J.3
-
39
-
-
79960962493
-
-
Baseline characteristics and mortality in ACCORD (abstract no. 88-OR). American Diabetes Association 69th Scientific Sessions, New Orleans (LA), June 5-9, 2009.
-
Calles J, Banerji M, Bonds DE, et al. Baseline characteristics and mortality in ACCORD (abstract no. 88-OR). American Diabetes Association 69th Scientific Sessions, New Orleans (LA), June 5-9, 2009.
-
-
-
Calles, J.1
Banerji, M.2
Bonds, D.E.3
-
40
-
-
77954159481
-
Epidemiologic relationships between A1C and all-cause mortality during a median 3.4-year follow-up of glycemic treatment in the ACCORD trial
-
Riddle MC, Ambrosius WT, Brillon DJ, et al. Epidemiologic relationships between A1C and all-cause mortality during a median 3.4-year follow-up of glycemic treatment in the ACCORD trial. Diabetes Care. 2010;33:983-990.
-
(2010)
Diabetes Care.
, vol.33
, pp. 983-990
-
-
Riddle, M.C.1
Ambrosius, W.T.2
Brillon, D.J.3
-
41
-
-
58149301489
-
Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA Diabetes Trials: a position statement of the American Diabetes Association and a Scientific Statement of the American College of Cardiology Foundation and the American Heart Association
-
Skyler JS, Bergenstal R, Bonow RO, et al. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA Diabetes Trials: a position statement of the American Diabetes Association and a Scientific Statement of the American College of Cardiology Foundation and the American Heart Association. J Am Coll Cardiol. 2009;53:298-304.
-
(2009)
J Am Coll Cardiol.
, vol.53
, pp. 298-304
-
-
Skyler, J.S.1
Bergenstal, R.2
Bonow, R.O.3
-
42
-
-
68449104156
-
Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study
-
Hemkens LG, Grouven U, Bender R, et al. Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia. 2009;52:1732-1744.
-
(2009)
Diabetologia.
, vol.52
, pp. 1732-1744
-
-
Hemkens, L.G.1
Grouven, U.2
Bender, R.3
-
43
-
-
68449094325
-
The influence of glucose-lowering therapies on cancer risk in type 2 diabetes
-
Currie CJ, Poole CD, Gale EA. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia. 2009;52:1766-1777.
-
(2009)
Diabetologia.
, vol.52
, pp. 1766-1777
-
-
Currie, C.J.1
Poole, C.D.2
Gale, E.A.3
-
44
-
-
68449094354
-
Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group
-
Colhoun HM. Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group. Diabetologia. 2009;52:1755-1765.
-
(2009)
Diabetologia.
, vol.52
, pp. 1755-1765
-
-
Colhoun, H.M.1
-
45
-
-
68449104625
-
Insulin glargine use and short-term incidence of malignancies-a population-based follow-up study in Sweden
-
Jonasson JM, Ljung R, Talback M, et al. Insulin glargine use and short-term incidence of malignancies-a population-based follow-up study in Sweden. Diabetologia. 2009;52:1745-1754.
-
(2009)
Diabetologia.
, vol.52
, pp. 1745-1754
-
-
Jonasson, J.M.1
Ljung, R.2
Talback, M.3
-
46
-
-
79960954712
-
-
US Food and Drug Administration. FDA Drug Safety Communication: update to ongoing safety review of Lantus (insulin glargine) and possible risk of cancer. .
-
US Food and Drug Administration. FDA Drug Safety Communication: update to ongoing safety review of Lantus (insulin glargine) and possible risk of cancer. 2011.
-
(2011)
-
-
-
47
-
-
0032841673
-
Diabetes in urban African-Americans. XVI. Overcoming clinical inertia improves glycemic control in patients with type 2 diabetes
-
Cook CB, Ziemer DC, El-Kebbi IM, et al. Diabetes in urban African-Americans. XVI. Overcoming clinical inertia improves glycemic control in patients with type 2 diabetes. Diabetes Care. 1999;22:1494-1500.
-
(1999)
Diabetes Care.
, vol.22
, pp. 1494-1500
-
-
Cook, C.B.1
Ziemer, D.C.2
El-Kebbi, I.M.3
-
48
-
-
0032511566
-
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)
-
UK Prospective Diabetes Study (UKPDS) Group.
-
UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352:854-865.
-
(1998)
Lancet.
, vol.352
, pp. 854-865
-
-
-
49
-
-
53749096863
-
10-year follow-up of intensive glucose control in type 2 diabetes
-
Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577-1589.
-
(2008)
N Engl J Med.
, vol.359
, pp. 1577-1589
-
-
Holman, R.R.1
Paul, S.K.2
Bethel, M.A.3
-
50
-
-
67149142042
-
A randomized trial of therapies for type 2 diabetes and coronary artery disease
-
Frye RL, August P, Brooks MM, et al. A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med. 2009;360:2503-2515.
-
(2009)
N Engl J Med.
, vol.360
, pp. 2503-2515
-
-
Frye, R.L.1
August, P.2
Brooks, M.M.3
-
51
-
-
60449089649
-
Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes
-
Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32:193-203.
-
(2009)
Diabetes Care.
, vol.32
, pp. 193-203
-
-
Nathan, D.M.1
Buse, J.B.2
Davidson, M.B.3
-
52
-
-
0038460302
-
The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report
-
Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289:2560-2572.
-
(2003)
JAMA.
, vol.289
, pp. 2560-2572
-
-
Chobanian, A.V.1
Bakris, G.L.2
Black, H.R.3
-
53
-
-
33749498694
-
Initial treatment with rosiglitazone/metformin fixed-dose combination therapy compared with monotherapy with either rosiglitazone or metformin in patients with uncontrolled type 2 diabetes
-
Rosenstock J, Rood J, Cobitz A, et al. Initial treatment with rosiglitazone/metformin fixed-dose combination therapy compared with monotherapy with either rosiglitazone or metformin in patients with uncontrolled type 2 diabetes. Diabetes Obes Metab. 2006;8:650-660.
-
(2006)
Diabetes Obes Metab.
, vol.8
, pp. 650-660
-
-
Rosenstock, J.1
Rood, J.2
Cobitz, A.3
-
54
-
-
77952083721
-
Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2years in patients with type 2 diabetes
-
Williams-Herman D, Johnson J, Teng R, et al. Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2years in patients with type 2 diabetes. Diabetes Obes Metab. 2010;12:442-451.
-
(2010)
Diabetes Obes Metab.
, vol.12
, pp. 442-451
-
-
Williams-Herman, D.1
Johnson, J.2
Teng, R.3
-
55
-
-
65549123794
-
Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial
-
Jadzinsky M, Pfutzner A, Paz-Pacheco E, et al. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial. Diabetes Obes Metab. 2009;11:611-622.
-
(2009)
Diabetes Obes Metab.
, vol.11
, pp. 611-622
-
-
Jadzinsky, M.1
Pfutzner, A.2
Paz-Pacheco, E.3
-
56
-
-
79955015666
-
Initial combination therapy with saxagliptin and metformin provides sustained glycaemic control and is well tolerated for up to 76weeks
-
Pfutzner A, Paz-Pacheco E, Allen E, et al. Initial combination therapy with saxagliptin and metformin provides sustained glycaemic control and is well tolerated for up to 76weeks. Diabetes Obes Metab. 2011;13:567-576.
-
(2011)
Diabetes Obes Metab.
, vol.13
, pp. 567-576
-
-
Pfutzner, A.1
Paz-Pacheco, E.2
Allen, E.3
-
57
-
-
0034641568
-
Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study
-
Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321:405-412.
-
(2000)
BMJ.
, vol.321
, pp. 405-412
-
-
Stratton, I.M.1
Adler, A.I.2
Neil, H.A.3
-
58
-
-
44649098307
-
Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation
-
Brunzell JD, Davidson M, Furberg CD, et al. Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation. Diabetes Care. 2008;31: 811-822.
-
(2008)
Diabetes Care.
, vol.31
, pp. 811-822
-
-
Brunzell, J.D.1
Davidson, M.2
Furberg, C.D.3
-
59
-
-
77951704587
-
Effects of combination lipid therapy in type 2 diabetes mellitus
-
Ginsberg HN, Elam MB, Lovato LC, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362:1563-1574.
-
(2010)
N Engl J Med.
, vol.362
, pp. 1563-1574
-
-
Ginsberg, H.N.1
Elam, M.B.2
Lovato, L.C.3
-
60
-
-
77954654472
-
Effects of medical therapies on retinopathy progression in type 2 diabetes
-
Chew EY, Ambrosius WT, Davis MD, et al. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med. 2010;363:233-244.
-
(2010)
N Engl J Med.
, vol.363
, pp. 233-244
-
-
Chew, E.Y.1
Ambrosius, W.T.2
Davis, M.D.3
-
61
-
-
0034994041
-
Low-dose combination therapy with colesevelam hydrochloride and lovastatin effectively decreases low-density lipoprotein cholesterol in patients with primary hypercholesterolemia
-
Davidson MH, Toth P, Weiss S, et al. Low-dose combination therapy with colesevelam hydrochloride and lovastatin effectively decreases low-density lipoprotein cholesterol in patients with primary hypercholesterolemia. Clin Cardiol. 2001;24:467-474.
-
(2001)
Clin Cardiol.
, vol.24
, pp. 467-474
-
-
Davidson, M.H.1
Toth, P.2
Weiss, S.3
-
62
-
-
0034802407
-
Coadministration of colesevelam hydrochloride with atorvastatin lowers LDL cholesterol additively
-
Hunninghake D, Insull W Jr, Toth P, et al. Coadministration of colesevelam hydrochloride with atorvastatin lowers LDL cholesterol additively. Atherosclerosis. 2001;158:407-416.
-
(2001)
Atherosclerosis.
, vol.158
, pp. 407-416
-
-
Hunninghake, D.1
Insull Jr, W.2
Toth, P.3
-
63
-
-
0035313336
-
Efficacy and safety of combination simvastatin and colesevelam in patients with primary hypercholesterolemia
-
Knapp HH, Schrott H, Ma P, et al. Efficacy and safety of combination simvastatin and colesevelam in patients with primary hypercholesterolemia. Am J Med. 2001;110:352-360.
-
(2001)
Am J Med.
, vol.110
, pp. 352-360
-
-
Knapp, H.H.1
Schrott, H.2
Ma, P.3
-
64
-
-
33645098531
-
Clinical utility of bile acid sequestrants in the treatment of dyslipidemia: a scientific review
-
Insull W Jr. Clinical utility of bile acid sequestrants in the treatment of dyslipidemia: a scientific review. South Med J. 2006;99: 257-273.
-
(2006)
South Med J.
, vol.99
, pp. 257-273
-
-
Insull Jr, W.1
-
65
-
-
25444497513
-
Safety and efficacy of colesevelam hydrochloride in combination with fenofibrate for the treatment of mixed hyperlipidemia
-
McKenney J, Jones M, Abby S. Safety and efficacy of colesevelam hydrochloride in combination with fenofibrate for the treatment of mixed hyperlipidemia. Curr Med Res Opin. 2005;21:1403-1412.
-
(2005)
Curr Med Res Opin.
, vol.21
, pp. 1403-1412
-
-
McKenney, J.1
Jones, M.2
Abby, S.3
-
66
-
-
33751238477
-
Lipid-lowering effects of colesevelam HCl in combination with ezetimibe
-
Bays H, Rhyne J, Abby S, et al. Lipid-lowering effects of colesevelam HCl in combination with ezetimibe. Curr Med Res Opin. 2006;22:2191-2200.
-
(2006)
Curr Med Res Opin.
, vol.22
, pp. 2191-2200
-
-
Bays, H.1
Rhyne, J.2
Abby, S.3
-
67
-
-
34147131830
-
Colesevelam hydrochloride-ezetimibe combination lipid-lowering therapy in patients with diabetes or metabolic syndrome and a history of statin intolerance
-
Rivers SM, Kane MP, Busch RS, et al. Colesevelam hydrochloride-ezetimibe combination lipid-lowering therapy in patients with diabetes or metabolic syndrome and a history of statin intolerance. Endocr Pract. 2007;13:11-16.
-
(2007)
Endocr Pract.
, vol.13
, pp. 11-16
-
-
Rivers, S.M.1
Kane, M.P.2
Busch, R.S.3
-
68
-
-
25844513563
-
Colesevelam HCl and ezetimibe combination therapy provides effective lipid-lowering in difficult-to-treat patients with hypercholesterolemia
-
Zema MJ. Colesevelam HCl and ezetimibe combination therapy provides effective lipid-lowering in difficult-to-treat patients with hypercholesterolemia. Am J Ther. 2005;12:306-310.
-
(2005)
Am J Ther.
, vol.12
, pp. 306-310
-
-
Zema, M.J.1
-
69
-
-
55949097996
-
Patient adherence and reimbursement amount for antidiabetic fixed-dose combination products compared with dual therapy among Texas Medicaid recipients
-
Cheong C, Barner JC, Lawson KA, Johnsrud MT. Patient adherence and reimbursement amount for antidiabetic fixed-dose combination products compared with dual therapy among Texas Medicaid recipients. Clin Ther. 2008;30:1893-1907.
-
(2008)
Clin Ther.
, vol.30
, pp. 1893-1907
-
-
Cheong, C.1
Barner, J.C.2
Lawson, K.A.3
Johnsrud, M.T.4
-
70
-
-
42449099867
-
Impact of fixed-dose combination drugs on adherence to prescription medications
-
Pan F, Chernew ME, Fendrick AM. Impact of fixed-dose combination drugs on adherence to prescription medications. J Gen Intern Med. 2008;23:611-614.
-
(2008)
J Gen Intern Med.
, vol.23
, pp. 611-614
-
-
Pan, F.1
Chernew, M.E.2
Fendrick, A.M.3
-
72
-
-
54049103635
-
Colesevelam hydrochloride therapy in patients with type 2 diabetes mellitus treated with metformin: glucose and lipid effects
-
Bays HE, Goldberg RB, Truitt KE, Jones MR. Colesevelam hydrochloride therapy in patients with type 2 diabetes mellitus treated with metformin: glucose and lipid effects. Arch Intern Med. 2008;168:1975-1983.
-
(2008)
Arch Intern Med.
, vol.168
, pp. 1975-1983
-
-
Bays, H.E.1
Goldberg, R.B.2
Truitt, K.E.3
Jones, M.R.4
-
73
-
-
49649095014
-
Colesevelam HCl improves glycemic control and reduces LDL cholesterol in patients with inadequately controlled type 2 diabetes on sulfonylurea-based therapy
-
Fonseca VA, Rosenstock J, Wang AC, et al. Colesevelam HCl improves glycemic control and reduces LDL cholesterol in patients with inadequately controlled type 2 diabetes on sulfonylurea-based therapy. Diabetes Care. 2008;31:1479-1484.
-
(2008)
Diabetes Care.
, vol.31
, pp. 1479-1484
-
-
Fonseca, V.A.1
Rosenstock, J.2
Wang, A.C.3
-
74
-
-
49449087092
-
Efficacy and safety of colesevelam in patients with type 2 diabetes mellitus and inadequate glycemic control receiving insulin-based therapy
-
Goldberg RB, Fonseca VA, Truitt KE, Jones MR. Efficacy and safety of colesevelam in patients with type 2 diabetes mellitus and inadequate glycemic control receiving insulin-based therapy. Arch Intern Med. 2008;168:1531-1540.
-
(2008)
Arch Intern Med.
, vol.168
, pp. 1531-1540
-
-
Goldberg, R.B.1
Fonseca, V.A.2
Truitt, K.E.3
Jones, M.R.4
|